Role of liposomal anthracyclines in breast cancer
Open Access
- 1 June 2007
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 18, vi70-vi73
- https://doi.org/10.1093/annonc/mdm229
Abstract
Anthracyclines are among the most effective drugs for patients with breast cancer. Their use, however, has been limited by associated toxic effects, including myelosuppression, alopecia, nausea and vomiting, stomatitis, and most importantly, cardiotoxicity. Liposomal anthracyclines were developed to increase the therapeutic index of conventional anthracyclines by maintaining antitumor efficacy while improving the safety profile. There are currently two liposomal formulations available for treatment of advanced disease: a not pegylated liposomal doxorubicin and a pegylated liposomal doxorubicin. This review will focus on both liposomal formulations of doxorubicin which are approved in Europe and Canada for use in patients with metastatic breast cancer.This publication has 20 references indexed in Scilit:
- Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancerAnnals of Oncology, 2004
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancerAnnals of Oncology, 2004
- Liposomal Anthracyclines and New Treatment Approaches for Breast CancerThe Oncologist, 2003
- Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast CancerThe Oncologist, 2003
- Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinomaCancer, 2001
- Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast CancerJournal of Clinical Oncology, 2001
- Cardiotoxicity of Chemotherapeutic AgentsDrug Safety, 2000
- Liposomal DoxorubicinJournal of Drug Targeting, 1996
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979
- Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor ResponseScience, 1977